Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley(Seagen (United States)), Stephen C. Alley(Seagen (United States)), Jamie B. Miyamoto(Seagen (United States)), Peter D. Senter(North Carolina Central University), Xinqun Zhang(Seagen (United States)), Russell J. Sanderson(Seagen (United States)), Dennis R. Benjamin(Seagen (United States)), Eric L. Sievers(Jackson-Madison County General Hospital)
Cited by 386
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825